# Study Comparing On-Demand Treatment With Two Prophylaxis Regimens Of BeneFIX In Patients With Severe Hemophilia B

> **NCT00364182** · PHASE3 · COMPLETED · sponsor: **Pfizer** · enrollment: 50 (actual)

## Conditions studied

- Hemophilia B

## Interventions

- **DRUG:** Recombinant Coagulation Factor IX (BeneFIX)
- **DRUG:** Recombinant Coagulation Factor IX (BeneFIX)

## Key facts

- **NCT ID:** NCT00364182
- **Lead sponsor:** Pfizer
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2007-05
- **Primary completion:** 2010-10
- **Final completion:** 2010-10
- **Target enrollment:** 50 (ACTUAL)
- **Last updated:** 2011-10-04


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00364182

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00364182, "Study Comparing On-Demand Treatment With Two Prophylaxis Regimens Of BeneFIX In Patients With Severe Hemophilia B". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT00364182. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*